Showing 68 news articles about Injectable & long-acting PrEP

Filters Content type: News Topic: Injectable & long-acting PrEP

The antiretroviral drug cabotegavir, administered every eight weeks as an injection, has been shown to be safe and effective in preventing HIV infection in men who have sex with men. Studies in women are ongoing and scientists are also working on a long-acting PrEP implant.

Injectable & long-acting PrEP

No HIV infections seen in groundbreaking trial of twice-yearly injectable PrEP

News
22 June 2024
Injectable & long-acting PrEP

TAF may be effective as once-weekly PrEP

News
10 May 2024
Injectable & long-acting PrEP

Why is the roll-out of injectable PrEP taking so long?

News
29 March 2024
Injectable & long-acting HIV treatment

Top 5 stories on injectable HIV treatment and PrEP from CROI 2024

News
25 March 2024
PrEP

Top 5 HIV PrEP stories from CROI 2024

News
21 March 2024
Injectable & long-acting PrEP

Ultra-long-acting cabotegravir could be taken three times a year for HIV PrEP and treatment

News
12 March 2024
HIV prevention policy

Huge increase in PrEP uptake when services offer choice, flexibility and injectable PrEP, African study shows

News
8 March 2024
Behaviour change interventions

PrEP marketing should not be a story about HIV, but a story about young women

News
23 January 2024
PrEP policies & guidelines

Zimbabwe shows how to make new HIV prevention products available quickly

News
4 January 2024
PrEP

Top 5 HIV PrEP stories from IAS 2023

News
25 August 2023
PrEP policies & guidelines

Injectable PrEP requires new testing procedures, IAS conference hears

News
17 August 2023
Finance & funding

Two modelling studies ask: will injectable PrEP ever be cost-effective at achievable prices?

News
1 August 2023
Injectable & long-acting HIV treatment

Top 5 stories on injectable HIV treatment and PrEP from CROI 2023

News
15 March 2023
New & experimental HIV treatments

Top 5 stories on new drugs for HIV prevention and treatment from CROI 2023

News
14 March 2023
Injectable & long-acting PrEP

Experimental islatravir implants protect monkeys against HIV-like virus

News
1 March 2023
PrEP science

HIV infections acquired while on injectable PrEP may take a very long time to be spotted

News
27 February 2023
Injectable & long-acting PrEP

Good news for women and PrEP: quarterly dosing may work

News
23 February 2023
Injectable & long-acting PrEP

Cabotegravir long-acting PrEP out of reach for upper middle-income nations

News
8 February 2023
The search for an HIV prevention vaccine

Closure of HIV vaccine study shows how far we have to go

News
19 January 2023
PrEP programmes & uptake

South Africa to begin piloting injectable PrEP in early 2023

News
7 November 2022
New & experimental HIV treatments

Merck restarts islatravir HIV treatment studies, but abandons monthly PrEP

News
23 September 2022
Transgender people

Injectable PrEP is just as effective for transgender women as it is for gay men, study analysis finds

News
11 August 2022
Injectable & long-acting PrEP

Injectable PrEP can only cost a little more than oral PrEP if it is to be cost-effective, South African study finds

News
3 August 2022
Access to healthcare

Just six injections a year can prevent HIV: here’s what it will take for the world to afford them

News
2 August 2022